Yan Wang1, Shenhui Wang2, Pengcai Shi2. 1. a Department of Anorectal Surgery and. 2. b Department of Anesthesiology , Shandong Provincial Qianfoshan Hospital, Shandong University , Ji'nan , China.
Abstract
PURPOSE: For the topical anesthetic, transcriptional transactivator peptide (TAT) modified lidocaine (LID) loaded nanostructured lipid carriers (TAT-NLCs-LID) were prepared and then used for improving transdermal delivery of local anesthetic drug. METHODS: In this study, TAT was conjugated with Distearoyl phosphatidylethanolamine-(polyethylene glycol)2000-maleimide (DSPE-PEG2000-Mal) to obtain TAT-PEG2000-DSPE. TAT-NLCs-LID were successfully prepared and characterized by determination of their particle size, morphology, drug encapsulation efficiency and in vitro drug release behavior. The skin permeation of LID-LNPs was examined using a Franz diffusion cell mounted with depilated mouse skin in vitro and in vivo anesthesia effect was evaluated on mice. RESULTS: The results showed that TAT-NLCs-LID have substantially small mean diameter (157.9 nm) and high encapsulation efficiency (81.8%). From the in vitro skin permeation results, transdermal flux of TAT-NLCs-LID was about several times higher than that of LID solution and NLCs-LID. In vivo anesthesia effect evaluation illustrated that TAT-NLCs-LID can enhance the transdermal delivery of LID by reducing the pain threshold in mice. CONCLUSION: These results indicate that the novel TAT containing drug delivery system is very useful for overcoming the barrier function of the skin and could deliver anesthetic through the skin. TAT-NLCs-LID could function as promising topical anesthetic system.
PURPOSE: For the topical anesthetic, transcriptional transactivator peptide (TAT) modified lidocaine (LID) loaded nanostructured lipid carriers (TAT-NLCs-LID) were prepared and then used for improving transdermal delivery of local anesthetic drug. METHODS: In this study, TAT was conjugated with Distearoyl phosphatidylethanolamine-(polyethylene glycol)2000-maleimide (DSPE-PEG2000-Mal) to obtain TAT-PEG2000-DSPE. TAT-NLCs-LID were successfully prepared and characterized by determination of their particle size, morphology, drug encapsulation efficiency and in vitro drug release behavior. The skin permeation of LID-LNPs was examined using a Franz diffusion cell mounted with depilated mouse skin in vitro and in vivo anesthesia effect was evaluated on mice. RESULTS: The results showed that TAT-NLCs-LID have substantially small mean diameter (157.9 nm) and high encapsulation efficiency (81.8%). From the in vitro skin permeation results, transdermal flux of TAT-NLCs-LID was about several times higher than that of LID solution and NLCs-LID. In vivo anesthesia effect evaluation illustrated that TAT-NLCs-LID can enhance the transdermal delivery of LID by reducing the pain threshold in mice. CONCLUSION: These results indicate that the novel TAT containing drug delivery system is very useful for overcoming the barrier function of the skin and could deliver anesthetic through the skin. TAT-NLCs-LID could function as promising topical anesthetic system.
Entities:
Keywords:
Lidocaine; local anesthetics; nanostructured lipid carriers; transcriptional transactivator peptide; transdermal drug delivery
Authors: Shahira F El Menshawe; Heba M Aboud; Mohammed H Elkomy; Rasha M Kharshoum; Amany M Abdeltwab Journal: Drug Deliv Transl Res Date: 2020-04 Impact factor: 4.617
Authors: Nicoleta Stoicea; Juan Fiorda-Diaz; Nicholas Joseph; Muhammad Shabsigh; Carlos Arias-Morales; Alicia A Gonzalez-Zacarias; Ana Mavarez-Martinez; Stephen Marjoribanks; Sergio D Bergese Journal: Drugs Date: 2017-07 Impact factor: 9.546